Dare BioscienceDARE +4.50%23 Days Payable is 458.51 as of Mar. 2026, which is 72% below its 10-year median of 1,638.18. GuruFocus rates DARE with a GF Score™ of 23/100. The stock has 4 warning signs investors should review. Among 706 Biotechnology companies, Dare Bioscience ranks better than 86.69% on this metric.
The historical rank and industry rank for Dare Bioscience's Days Payable or its related term are showing as below:
DARE'
s Days Payable Range Over the Past 10 Years
Min: 1075.05 Med: 1638.18 Max: 1638.18
Current: 1075.05
During the past 13 years, Dare Bioscience's highest Days Payable was 1638.18. The lowest was 1075.05. And the median was 1638.18.
DARE's Days Payable is ranked better than 86.69% of 706
companies
in the Biotechnology industry
Industry Median: 113.56
vs DARE: 1075.05
Dare Bioscience's Days Payable
increased
from Mar. 2025 (0.00) to Mar. 2026 (458.51).
It may suggest that Dare Biosciencedelayed paying its suppliers.
Dare Bioscience Days Payable Related Terms
Dare Bioscience Days Payable Historical Data
* Premium members only.
The historical data trend for Dare Bioscience's Days Payable can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Biotechnology subindustry, Dare Bioscience's Days Payable, along with its competitors' market caps and Days Payable data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Dare Bioscience Days Payable vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Dare Bioscience's Days Payable distribution charts can be found below:
* The bar in red indicates where Dare Bioscience's Days Payable falls into.
Days Payable indicates the number of days that the account payable relative to cost of goods sold the company has. An increase of Days Payable may suggest that the company delays paying its suppliers.
Dare Bioscience's Days Payable for the fiscal year that ended in Dec. 2025 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Dare Bioscience (DARE) has a Days Payable of 458.51 as of Mar. 2026. Days payable represents the average amount of days a company waits to pay its invoices from suppliers. View historical data on Dare Bioscience and its competitors. This is 72% below median its historical median of 1,638.18. Over the past decade, Dare Bioscience's Days Payable has ranged from 1,075.05 to 1,638.18. According to the industry distribution chart, Dare Bioscience ranks #94 out of 706 companies in the Biotechnology industry, placing it in the top 13.3%.
Is Dare Bioscience's Days Payable too high?
Dare Bioscience's current Days Payable of 458.51 is 72% below median its 10-year median of 1,638.18. Over the past 10 years, this metric has ranged from a low of 1,075.05 to a high of 1,638.18. The Biotechnology industry median Days Payable is 113.56. Dare Bioscience's value of 458.51 is 303.8% above this industry median. Based on the distribution chart, Dare Bioscience ranks #94 out of 706 companies in the Biotechnology industry, which is in the top quartile — a strong position relative to peers. Overall, Dare Bioscience has a GF Score™ of 23/100, reflecting its overall financial health beyond just this single metric.
How does Dare Bioscience's Days Payable compare to TVGN and LITS?
According to the Biotechnology industry distribution chart, Dare Bioscience ranks #94 out of 706 companies for Days Payable. This places Dare Bioscience in the top 13% of its industry — outperforming the majority of peers. The industry median Days Payable is 113.56. Dare Bioscience's value of 458.51 is 303.8% above this benchmark. Historically, Dare Bioscience's own Days Payable has ranged from 1,075.05 to 1,638.18 over the past decade. While the company's 10-year median is 1,638.18 vs. the industry median of 113.56, Dare Bioscience has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Days Payable for a Biotechnology company?
The median Days Payable among Biotechnology companies is 113.56, based on 706 companies in the industry. Companies in the top quartile (top 25%) have a Days Payable significantly above this median, while those in the bottom quartile fall well below. However, Days Payable should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Dare Bioscience's current Days Payable of 458.51 is 303.8% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Days Payable mean?
A high Days Payable can signal that a stock is expensive relative to its fundamentals. Days payable represents the average amount of days a company waits to pay its invoices from suppliers. View historical data on Dare Bioscience and its competitors. For the Biotechnology industry, the median Days Payable is 113.56 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Dare Bioscience's current Days Payable is 458.51, which is 72% below median its own 10-year median of 1,638.18. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Dare Bioscience stock overvalued right now?
Dare Bioscience (DARE) has a current Days Payable of 458.51. The current Days Payable is 458.51, which is 72% below median its 10-year median of 1,638.18 and 303.8% above the Biotechnology industry median of 113.56. Dare Bioscience's overall GF Score™ is 23/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Days Payable calculated?
Days Payable is calculated from a company's financial statements. For Dare Bioscience (DARE), the current Days Payable is 458.51 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Dare Bioscience Inc is a biopharmaceutical company committed to advancing products for women's health. The company identifies, develops, and brings to market a diverse portfolio of differentiated therapies that prioritize women's health and well-being, expand treatment options, and improve outcomes, in the areas of contraception, fertility, and vaginal and sexual health. The company's first product, XACIATO is a single-dose vaginal gel prescription product for the treatment of bacterial vaginosis in females 12 years of age and older. The company's portfolio includes two product candidates in clinical development namely, Ovaprene and Sildenafil Cream. It has one operating segment, women's health.
23GF Score
Get the complete analysis for DARE
Days Payable is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
DARE has been successfully added to your 
